Abstract
Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Current Pharmaceutical Design
Title: Disease Modifying Approaches for Alzheimers Pathology
Volume: 13 Issue: 19
Author(s): Marcin Sadowski and Thomas Wisniewski
Affiliation:
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Abstract: Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Export Options
About this article
Cite this article as:
Marcin Sadowski and Thomas Wisniewski , Disease Modifying Approaches for Alzheimers Pathology, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039788
DOI https://dx.doi.org/10.2174/138161207781039788 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Innate and Adaptive Immune Responses in Chronic HCV Infection
Current Drug Targets An Update on Autoinflammatory Diseases
Current Medicinal Chemistry The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity
Central Nervous System Agents in Medicinal Chemistry Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Renal Function, Albumin-Creatinine Ratio and Pulse Wave Velocity Predict Silent Coronary Artery Disease and Renal Outcome in Type 2 Diabetic and Prediabetic Subjects
Current Hypertension Reviews Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Biosafety of Adenoviral Vectors
Current Gene Therapy From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews